Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ESPR. JMP Securities reaffirmed a “market outperform” […]
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ESPR. JMP Securities reaffirmed a “market outperform” […]
